The stock of PTC Therapeutics Inc. (NASDAQ:PTCT) increased by $1.4 on Tuesday to finish at $25.68, up 5.77 percent. The last five days have seen an average of 3,462,060 shares of common stock traded. 22 times new highs were reached in the current year, with a fall of -$12.49. The average number of shares traded over the last 20 days was 1,140,850, while the average volume over the last 50 days totaled 842,960.
PTCT stock dropped -34.86% since last month. On 09/19/23, the company’s shares reached a one-month low of $23.57. The stock touched a high of $59.84 on 05/22/23, after rallying from a low of $23.83 in 52 weeks. The price of PTCT stock has declined by -32.72% or -$12.49 this year, reaching a new high 22 times. Still, the stock price is down -57.09% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
PTCT stock investors should be aware that PTC Therapeutics Inc. (PTCT) stock had its last reported insider trading activity 14 days ago on Sep 06. On Sep 06, Director Young Alethia sold 11,666 shares at $39.86 each. This transaction resulted in the insider making $464,972. On Jun 07, SCHMERTZLER MICHAEL sold 1,000 shares at a price of US$44.86. After the transaction, the insider now owns 116,766 shares. Director Reeve Emma had earlier sold 2,652 shares on May 23 for $59.53 a share. The transaction was completed for $157,885.
Financial Health
For the three months ended June 29, PTC Therapeutics Inc.’s quick ratio was 1.20, while its current ratio was 1.20, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 93.70% percent. PTC Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -43.10%, whereas its operating margin stood at -72.80% for the same period. Based on annual data, it had gross profit of $654.12 million and revenue of $698.8 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PTCT’s return on assets (ROA) during the last 12 months has been -39.70%. There was a -41.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 153.50%.
Earnings Surprise
According to PTC Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $213.81 million, while revenues rose by 22.58% to $220.38 million. It was predicted that PTC Therapeutics Inc.’s quarterly earnings would be -$2.66, but it ended up being -$1.24, beating the consensus by -114.50%. EBITDA was $59.82 million for the quarter. At the end of PTC Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 1.92 billion, while its total debt was $1.47 billion. Equity owned by shareholders amounts to $75.34 million.
Technical Picture
Here’s a quick look at PTC Therapeutics Inc.’s (PTCT) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 18.72%, suggesting the stock is oversold, with a 176.18% historical volatility rate.
The stochastic %K and %D were 8.16% and 15.21% respectively, while the average true range (ATR) was 2.83. Based on the 14-day stochastic reading of 11.52%, the RSI (14) reading is 22.39%. On the 9-day MACD Oscillator, the stock is at -9.66, and the 14-day reading is at -11.37.
Analyst Ratings
PTC Therapeutics Inc. (NASDAQ: PTCT) was downgraded by Citigroup to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned PTC Therapeutics Inc. (PTCT) an Hold rating. PTCT is a stock that is recommended for selling by 2 brokerage firms, while 7 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is PTCT’s price target for the next 12 months?
The current consensus forecast for the stock is between $22.00 and $73.00, with a median target price of $31.00. In analyzing these forecasts, the average price target given by analysts for PTC Therapeutics Inc. (PTCT) is $38.15.
